Creation of ceftazidime-avibactam utilization evaluation standards to examine physician prescribing compliance: a retrospective study
DOI:
https://doi.org/10.1590/s2175-97902026e24731Keywords:
Ceftazidime-avibactam, Drug Utilization Evaluation, Standards, Infectious disease, ComplianceAbstract
A study was conducted to create drug utilization evaluation (DUE) standards for ceftazidime-avibactam (CZA) and evaluate CZA use at the First Affiliated Hospital of Bengbu Medical University, China, from May 26, 2020, to December 18, 2024. First, we organized an expert panel and created DUE standards for CZA. Then, we performed an observational study and evaluated the physician CZA prescribing behaviors, which were compared to the DUE standards and calculated the compliance rates. The DUE CZA standards had medication indications, management metrics, administration process, and treatment outcomes. Sixty-four patients received the CZA during the study period. There was satisfactory compliance between CZA prescription and DUE standards regarding route, solvent, incompatibility, and contraindications. However, the compliance rates for CZA indication, dosage regimen, infusion time, combination therapy, drug interaction, and duration of treatment were 68.8% (44/64), 65.6% (42/64), 29.7% (19/64), 73.3% (44/60), 43.8% (28/64), and 62.5% (40/64), respectively. The pre-CZA bacteria culture test was 96.9% (62/64). In addition, medical records and prescription authorization were 95.3% (61/64) and 71.9% (46/64) compliant, respectively. No adverse reactions were reported. In conclusion, the CZA DUE standards could be applied to identify inappropriate prescriptions for improvements.
Downloads
References
Arain S, Khalawi F, Parakkal SA, Alhamad HS, Thorakkattil SA, Alghashmari FFJ, et al. Drug Utilization Evaluation and Impact of Pharmacist Interventions on Optimization of Piperacillin/Tazobactam Use: A Retrospective Analysis and Prospective Audit. Antibiotics (Basel). 2023;12(7):1192.
Auwaerter PG, Bartlett JG, Dzintars K, Kilcrease C, Chalk BS. The Johns Hopkins POC-IT ABX Guide The Johns Hopkins POC-IT Center. 2023:https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540602/all/__About__#540602.
Bakdach D, Elajez R, Bakdach AR, Awaisu A, De Pascale G, Ait Hssain A. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. J Clin Med. 2022;11(23):6898.
Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15(3):89-100.
Bian J, Li Q, Li J, Yang N, Zhang W, Mei D, et al. Guideline for the evaluation of prescription appropriateness. Ann Transl Med. 2021;9(16):1352.
Che H, Wang R, Wang J, Cai Y. Ceftazidime/avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: A meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2019;54(6):809-813.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
Curtiaud A, Petit M, Chommeloux J, Pineton De Chambrun M, Hekimian G, Schmidt M, et al. Ceftazidime/avibactam serum concentration in patients on ECMO. J Antimicrob Chemother. 2024;79(5):1182-1186.
De La Calle C, Rodríguez O, Morata L, Marco F, Cardozo C, García-Vidal C, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agentes. 2019;53(4):520-524.
Jorgensen SC, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, et al. Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections. Open Forum Infect Dis. 2019;6(12):ofz522.
Li J, Lovern M, Riccobene T, Carrothers TJ, Newell P, Das S, et al. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. Antimicrob Agents Chemother. 2020;64(4):e02105-02119.
Manning N, Balabanian G, Rose M, Landman D, Quale J. Activity of ceftazidime–avibactam against clinical isolates of Klebsiella pneumoniae, including KPC-carrying isolates, endemic to New York City. Microb Drug Resist. 2018;24(1):35-39.
Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, et al. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Ch. 2019;63(8):10.1128/aac. 00779-00719.
Ministry of Health of China. Management of Clinical Application of Antimicrobial Drugs [S]. 2015-8-27.
Nwankwo L, Butt Z, Schelenz S. Experience of Ceftazidime/avibactam in a UK tertiary cardiopulmonary specialist center. Expert Rev Anti Infect Ther. 2021;19(1):101-108.
Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E. Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist. 2019;25(9):1357-1364.
Paulson HL, Albin RL. Huntington's Disease: Clinical Features and Routes to Therapy. In: Neurobiology of Huntington's Disease: Applications to Drug Discovery. Edited by Lo DC, Hughes RE. Boca Raton (FL): CRC Press/Taylor & Francis. Front neurosci-switz. 2011:Chapter 1.
Phillips MS, Gayman JE, Todd MW. ASHP guidelines on medication-use evaluation. American Society of Health-system Pharmacists. Am J Health Syst Pharm. 1996;53(16):1953-1955.
Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. Clin Infect Dis. 2019;68(3):519-524.
Qingping S, Feng D, Ran S, Yan L, Haoyu Y, and Meiling Y. Drug use evaluation of cefepime in the first affiliated hospital of Bengbu medical college: a retrospective and prospective analysis. BMC Infect Dis. 2013;13(1):1-7.
Sanford JP, Et Al. The Sanford Guide to Antimicrobial Therapy 2020 (50th edition) [M]. Peking Union Medical College Press (Beijing, China). 2021:239.
Sousa A, Pérez-Rodríguez MT, Soto A, Rodríguez L, Pérez-Landeiro A, Martínez-Lamas L, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemoth. 2018;73(11):3170-3175.
Strich JR, Ricotta E, Warner S, Lai YL, Demirkale CY, Hohmann SF, et al. Pharmacoepidemiology of ceftazidime-avibactam use: a retrospective cohort analysis of 210 US hospitals. Clin Infect Dis. 2021;72(4):611-621.
Tang B, Cui N. [Several key points that need to be concerned in the clinical application of ceftazidime/avibactam]. Zhonghua Yi Xue Za Zhi. 2021;101(41):3365-3370.
The Editorial Board. Expert Consensus on the Clinical Application of β-Lactam Antibiotic/β-Lactamase Inhibitor Combinations. Chinese Med J-Peking. 2020;100(10):738-747.
Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285-295.
Tsolaki V, Mantzarlis K, Mpakalis A, Malli E, Tsimpoukas F, Tsirogianni A, et al. Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients. Antimicrob Agents Chemother. 2020;64(3):e02320-02319.
Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis. 2021;73(9):1664-1676.
Us Fda. Avycaz (ceftazidime and avibactam) for injection, for intravenous use: US prescribing information. https://www. accessdata.fda.gov. 2018:Accessed 16 Mar 2018.
Vena A, Giacobbe DR, Castaldo N, Cattelan A, Mussini C, Luzzati R, et al. Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. Antibiotics (Basel). 2020;9(2):71.
Wang Q, Xu P, Zhou Y. Analysis of the clinical application of ceftazidime-avibactam in China. J Infect Public Health. 2022;15(4):455-459.
Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime–avibactam and underlying mechanisms. J Glob Antimicrob Re. 2020;22:18-27.
Yao J, Li T, Li Z, Jiao H. Establishment and application of drug use evaluation criteria for ceftazidime-avibactam. J Medical Forum. 22020;41(10):66-69.
Downloads
Published
Data Availability Statement
The datasets generated and/or analyzed during the current study are not publicly available due to limitations of ethical approval involving patient data and anonymity, but are available from the corresponding author upon reasonable request.
Issue
Section
License
Copyright (c) 2026 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
